Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Tunnel vision or global outlook? Global Pharma's preoccupation with the US.

COVID-19 is a litmus test of whether health systems can pool assets and expertise and fairly distribute resources so that patients worldwide can benefit equally, writes Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation.

Date

16 July 2020

Download the full publication

COVID-19 is exposing three pre-existing fault-lines in this system: a heavy dependency on donors to sustain access mechanisms; countries’ dependency on a few large pharmaceutical companies for supply, due to the lack of local availability of manufacturing capacity of essential medicines; and the preoccupation that some pharmaceutical companies have with high profit margins and with the US market in particular, which limits their ability to play a strong role in curbing this pandemic globally. 

Conversely, other companies that have made strides in recent years in terms of building local supply chain and manufacturing capacity, and that are building up steady businesses and networks in low- and middle-income countries. At the same time, they have achieved a balance with their businesses in lucrative markets. These are the companies that are now showing their capacity as truly global players, and proving to be resilient in the face of this pandemic. 


Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved